Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.
Abstract
Background and Purpose Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. Methods Eighty-five patients received perampanel between March 2016 and August 2016. Patients were divided into two groups according to their dosing schedule: rapid dose titration (2-mg increments at intervals of 1 to 2 weeks) and slow dose titration (2-mg increments at intervals of at least 3 weeks). Seizure frequency and adverse events were analyzed over 3 months. Results Adverse events were reported by 47 (58%) of the 81 patients analyzed, with 12 (15%) patients discontinuing perampanel due to adverse events. Common adverse events included dizziness (n=30, 37%), aggressive mood and behavior (n=19, 24%), gait disturbance (n=16, 20%), and sleep problems (n=10, 12.4%). The overall adverse events were similar in the slow-titration group (38 of 61 patients) and the rapid-titration group (8 of 20 patients, p=0.081). However, none of the 20 patients in the slow-titration group experienced gait disturbance, compared with 16 of the 61 patients in the rapid-titration group (p=0.009), while appetite change was experienced by 4 patients in the slow-titration group but only 1 in the rapid-titration group (p=0.003). No relationship was noted between adverse events and the maximum dose of perampanel (p=0.116). Sex differences were observed, with the response to perampanel being better and the rate of adverse events being higher in females (p=0.015 and p=0.046, respectively). Conclusions Slow titration of perampanel may reduce perampanel-related adverse events.
참고문헌 (18)
- Rogawski MA, "Revisiting AMPA receptors as an antiepileptic drug target", Epilepsy Curr, 11, pp.56~63 (2011)[DOI]
- French JA, "Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304", Neurology, 79, pp.589~596 (2012)[DOI]
- French JA, "Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305", Epilepsia, 54, pp.117~125 (2013)[DOI]
- Krauss GL, "Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures", Neurology, 78, pp.1408~1415 (2012)[DOI]
- De Liso P, "Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: an Italian observational multicenter study", Epilepsy Res, 127, pp.93~100 (2016)[DOI]
- Steinhoff BJ, "A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria", Epilepsy Res, 108, pp.986~988 (2014)[DOI]
- Steinhoff BJ, "First clinical experiences with perampanel--the Kork experience in 74 patients", Epilepsia, 55(Suppl 1), pp.16~18 (2014)
- Shah E, "Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: a UK and Ireland multicentre study", Seizure, 34, pp.1~5 (2016)[DOI]
- Heyman E, "Tolerability and efficacy of perampanel in children with refractory epilepsy", Dev Med Child Neurol, 59, pp.441~444 (2017)[DOI]
- Biro A, "Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences", Neuropediatrics, 46, pp.110~116 (2015)[DOI]
- Patsalos PN, "The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist", Epilepsia, 56, pp.12~27 (2015)[DOI]
- Fisher RS, "The new classification of seizures by the international league against epilepsy 2017", Curr Neurol Neurosci Rep, 17, pp.48~ (2017)[DOI]
- Schalock RL, "Intellectual disability: definition, classification, and systems of supports", American Association on Intellectual and Developmental Disabilities, ~ (2010)
- Trinka E, "Perampanel for focal epilepsy: insights from early clinical experience", Acta Neurol Scand, 133, pp.160~172 (2016)[DOI]
- Gidal BE, "Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures", Epilepsia, 54, pp.1490~1497 (2013)[DOI]
- Franconi F, "Gender differences in drug responses", Pharmacol Res, 55, pp.81~95 (2007)[DOI]
- Vazquez B, "Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures", Epilepsia, 56, pp.e90~e94 (2015)[DOI]
- Villanueva V, "Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures", Epilepsy Res, 127, pp.126~134 (2016)[DOI]